NCT01946204 2026-04-13
SPARTAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Clinical Trials
26 trialsNCT02257736 2026-04-13
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02489318 2026-04-13
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02772588 2026-04-13
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04108208 2026-04-13
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT04325828 2026-04-13
YATAGARASU
Janssen Pharmaceutical K.K.
Phase 2 Active not recruiting
NCT04530552 2026-04-01
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03412396 2026-03-19
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01171898 2026-02-24
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT03503344 2026-01-21
PILLAR
University of California, San Francisco
Phase 2 Completed
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT03098836 2025-09-12
PANTHER
Duke University
Phase 2 Completed
NCT03298087 2025-08-01
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
VA Office of Research and Development
Phase 2 Completed
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06151418 2025-06-04
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Pfizer
Completed
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT04523207 2025-04-25
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Janssen Research & Development, LLC
Phase 2 Completed
NCT03777982 2024-09-19
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Dana-Farber Cancer Institute
Phase 3 Terminated
NCT03311555 2024-03-19
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Duke University
Phase 2 Completed
NCT02721979 2023-02-09
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
University of Washington
Phase 2 Terminated
NCT03279250 2022-08-10
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02770391 2022-06-21
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02849990 2022-01-13
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
University of Washington
Phase 2 Completed
NCT03093272 2020-04-09
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed